Author

Asfar S. Azmi

Wayne State University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Amro AboukameeliD· 2 shared Bassel F. El‐RayesiD· 2 shared Boris PascheiD· 2 shared Herbert R. CheniD· 2 shared Hugo JimeneziD· 2 shared Husain Yar KhaniD· 2 shared Md. Hafiz UddiniD· 2 shared Miguel E. ToboniD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Amro AboukameelORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways

Md. Hafiz Uddin, Zaid K Mahdi, Irfana Muqbil, Brendon Herring, Rose J. Bart, Husain Yar Khan, Yiwei Li, Amro Aboukameel, Sahar F. Bannoura, Hugo Jimenez, Allan M. Johansen, Mohammad Najeeb Al-Hallak, Ibrahim Hanna Azar, Amr Mohamed, Tarik H. Hadid, , Asfar S. Azmi

This study identifies key oncogenic pathways and targetable genes in MEN1-wild-type low-grade pancreatic NETs that drive metastasis, offering a therapeutic strategy based on pathway intensity rather than mutation count.

International Journal of Biological Sciences · Sep 3, 2026Peer-reviewedCancer Biology

PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer

Sahar F. Bannoura, Husain Yar Khan, Amro Aboukameel, Yin Wan, Bin Bao, Md. Hafiz Uddin, Hugo Jimenez, Adeeb Aboukameel, Rayyan Siddiqui, Filza Khan, Pouya Haratipour, Long Gu, Rafic Beydoun, M. W. Saif, Miguel E. Tobon, , Asfar S. Azmi

This study shows that combining PCNA inhibitor AOH1996 with KRAS inhibitors enhances antitumor activity in pancreatic cancer models.

bioRxiv · Dec 10, 2025 · PreprintCancer Biology